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Abstract
The treatment of HCV infection has seen significant progress, particularlysince the
approval of new direct-acting antiviral drugs. However these clinical achievements have
beenmade despite an incomplete understanding of HCV replication and within-host evolu-
tion, especially comparedwith HIV-1. Here, we undertake a comprehensive analysis of
HCV within-host evolution during chronic infection by investigating over 4000 viral
sequences sampled longitudinally from 15 HCV-infected patients. We compare our HCV
results to those from a well-studied HIV-1 cohort, revealing key differences in the evolution-
ary behaviour of these two chronic-infecting pathogens. Notably, we find an exceptional
level of heterogeneity in the molecular evolution of HCV, both within and among infected
individuals. Furthermore,these patterns are associated with the long-termmaintenance of
viral lineages within patients, which fluctuate in relative frequency in peripheral blood.
Together, our findings demonstrate that HCV replication behavior is complex and likely
comprisesmultiple viral subpopulationswith distinct evolutionary dynamics. The presence
of a structured viral population can explain apparent paradoxes in chronic HCV infection,
such as rapid fluctuations in viral diversity and the reappearance of viral strains years after
their initial detection.
Author Summary
Our knowledge of HCV within-host evolution is substantially limited, which is surprising
given that highly successful therapies against the virus have been developed. Key aspects of
HCV infection, such as rapid fluctuations in viral diversity and the reappearance of viral
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strains years after their initial detection, remain unexplained. To better understand this
problem, we analyse viral sequences from HCV-infected patients sampled over several
years. Our findings suggest that the replication dynamics during chronic HCV infection
are distinct from those of HIV-1, and dominated by the co-circulation of multiple viral
strains. Although a major difference between the two chronic-infecting viruses is the level
of recombination, our results indicate that HCV within-host evolution is most likely to be
shaped by a structured viral population. Crucially, our study shows that HCV sampled
from blood does not fully represent the within-host viral population at that time. This may
have important implications for HCV treatment, especially in patients that have seemingly
cleared the virus, as well as for molecular epidemiology studies investigating HCV
transmission.
Introduction
An estimated 3% of the global human population has been infected with the hepatitis C virus
(HCV), many of whom are unaware of their infection status. Unlike other members of the
virus family Flaviviridae, HCV causes acute and chronic infection in humans. Symptoms of
acute infection are typically mild and, despite the early response mounted by the immune sys-
tem, viral clearance occurs in only 15–20% of untreated cases. In the remaining individuals
who become chronically-infected, the virus can, over many years, cause liver cirrhosis, hepato-
cellular carcinoma, and other related diseases. Genetically, HCV is a very diverse virus and up
to 50% of nucleotide sites may vary among HCV strains belonging to different genotypes. The
high genetic diversity of HCV is the product of both a high rate of molecular evolution and a
proposed long-term association of the virus with human populations [1].
Prior to the discovery in 2003 of an atypical HCV genotype 2 strain that can readily replicate
in hepatoma cell lines [2], the development of HCV-specific antiviral drugs was comparatively
slow and, until recently, standard drug treatment for HCV infectionwas non-specific and
involved long courses of interferon and ribavirin. However, newly approved direct-acting anti-
viral (DAA) drugs that target the HCV life cycle are highly effective, leading to viral clearance
in>90% of patients within 12 to 24 weeks of treatment [3–7]. Interestingly, these clinical suc-
cesses have been achieved despite relatively little being known about the in vivo dynamics of
HCV replication, host cell infection, and evolution.
Most of our understanding of HCV replication behaviour within infected individuals has
come frommathematical models of virus kinetics [8], which are typically fitted to measure-
ments of viral load from longitudinal samples of peripheral blood. Simple models that employ
a mass actionmechanism of infection can explain the two-phase decline in HCV viral load fol-
lowing interferon-based drug therapy and have demonstrated (i) a high turnover of virions in
peripheral blood [9], (ii) a high variance among patients in the mean lifespan of infected cells,
ranging from 2–70 days [9], and (iii) that approximately 3% of virions in serum result from
extra-hepatic replication [10]. More complex viral load dynamics, including triphasic decline
and the failure of drugs to fully eradicate the virus, have been explained by adding proliferation
of infected and non-infected hepatocytes to the model [11]. However, it is unclear whether
division of infected hepatocytes requires active virus replication, or whether HCV is passively
transferred between parent and daughter cells.
An alternate hypothesis, that HCV persists in exceptionally long-lived cells during chronic
infection, has been discounted [11, 12]; yet it is known that uninfected hepatocytes have a sig-
nificantly slower turnover than the main target cells of HIV (CD4+ T lymphocytes) and are
Exceptional Heterogeneity in Viral EvolutionaryDynamics Characterises Hepatitis C Virus Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005894 September 15, 2016 2 / 20
is supported by the intramural research program of
the National Institute of Allergy and Infectious
Diseases (NIAID). PK is supported by WT grant
(WT091663MA), the Oxford Martin School and the
NIHR Biomedical Research Centre, Oxford. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests:RR is employed by
BioInfExperts as bioinformatics consultant.
thought to survive for years [13]. Further, despite the important insights revealed by mass-
actionmodels of HCV virus kinetics, they cannot fully reconcile all aspects of chronic HCV
infection in vivo. This includes observations of cell-to-cell virus transmission [14–16], foci of
infectionwithin the liver [17–21], and viral re-emergence after drug therapy has temporarily
reduced viremia in peripheral blood to undetectable levels [22–25].
Standard models of virus infection kinetics were initially developed in the context of HIV-1
infection [26, 27], in which virions sampled from peripheral blood appear to be representative
of the contemporaneous population of actively-infected host cells. Whether this assumption is
also true for HCV is difficult to ascertain because sampling of liver tissue, the primary site of
replication, is invasive and rarely repeated longitudinally during infection.Molecular and
mathematical analysis of individual liver biopsy samples indicates that HCV infection spreads
locally within the liver and is likely to be seeded randomly by viruses from peripheral blood
[28]. Further, analysis of virus gene sequences obtained from transplantation patients and
from explant livers suggests that hepatic and extra-hepatic viruses can be genetically distinct
and may form different sub-populations [29–32]. Recent experimental and clinical studies
have suggested a more complex model of HCV replication, involving cell-to-cell transmission
dampened by localized immune responses, as well as detectable virus replication in quiescent
hepatocytes (i.e. cells that are differentiated but in a resting state) and non-hepatic reservoirs
[10, 33]. Importantly, these observations suggest that viral replication dynamics during HCV
infectionmay be decoupled, at least in part, from host cell turnover.
Viral gene sequences, sampled longitudinally through time from chronically infected
patients, constitute a valuable and independent source of information about replication
dynamics. The highmutation of HCVmeans that viral genomes accrue ~0.3 to 1.2 nucleotide
substitutions per cell infection [34, 35]. As a consequence, the genetic divergence between
viruses sampled throughout infection will be influenced by both the mode and tempo of cell-
to-cell infection. Investigation of longitudinally sampled virus sequences has proven useful for
HIV-1 infection, leading to insights regarding the size of viral bottlenecks at transmission [36–
38], correlations between viral evolution and clinical outcomes [39, 40], and the relationship
betweenwithin- and among-host virus evolution [41]. Studies of serially-sampledHCV
sequences have also indicated a link between viral evolution and disease progression. First, the
level of HVR1 diversity during acute infection has been associated with whether a patient suc-
cessfully clears the virus [42]. Second, greater genetic diversity and synonymous divergence is
observed in viral populations sampled from rapid progressors, which suggests that faster dis-
ease progression is associated with shorter viral generation times [43], as has also been reported
for HIV-1 [40]. Nonetheless, these observations are based on studies with limited number of
patients and viral sequences, and which used only simple summary statistics (e.g. pairwise
diversity) during analysis.
To better understand the replication dynamics of HCV during infection, we undertake a
comprehensive analysis of HCV evolutionary dynamics during chronic infection.We use sta-
tistically powerful Bayesian phylogenetic approaches to test hypotheses concerning the diver-
sity and divergence through time of within-host HCV populations. In total, we analyse more
than 4000 viral gene sequences obtained from 15 patients, sampled over 100 different time
points. We compare our HCV results to those obtained from nine comparable HIV-1 infected
subjects, and discover differences between the evolutionary dynamics of the two viruses during
chronic infection.Most notably we observe significant heterogeneity in the molecular evolution
of HCV, both among patients and over time, which contrasts with more consistent trends in
HIV-1 infected patients. Our results support a complex model of HCV replication dynamics
during chronic infection that reconciles apparent paradoxes observed in the natural history of
this infection
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Results
Per sample summarystatistics
The amount of diversity among viruses sampled at each time point is shown in Fig 1A, where
the size of each circle is proportional to the mean pairwise sequence diversity (MPD) for that
time-point. If we average the MPD scores across all subjects and time points then we obtain
0.009 changes/site for the HCV untreated group and 0.013 changes/site for the HCV treated
group. The overall genetic diversity is higher for HIV-1 patients (average MPD across all time
points = 0.029). We also found interesting differences betweenHIV-1 and HCV patients in the
distribution of viral diversity among time points. Specifically, we find that the distribution of
MPD scores for the HIV-1 group is much more symmetric (skewness = 0.37) than for the two
HCV cohorts (skewness = 1.38 and 2.08, for HCV treated and untreated subjects, respectively;
Fig 1B). The strong positive skew observed for both HCV groups indicates that, during infec-
tion, HCV exhibits more extreme occasional shifts to high viral diversity, despite the fact that,
on average, viral population diversity is low compared to HIV-1 infections. Treatment periods
(interferon and ribavirin) in the HCV treated group do not appear to correlate with lower
genetic diversity, although this cannot be formally tested because the relative timing of sam-
pling times and treatment periods varied among subjects.
To characterize change in the genetic structure of the within-host viral population we calcu-
lated Tajima’s D statistic for each time point in each patient (Fig 1C–1E). This statistic varies sig-
nificantly over the course of infection in HCV patients, with rapid fluctuations even between
immediately adjacent time points (Fig 1C and 1D). This demonstrates substantial changes in the
frequency distribution of polymorphic sites. In other words, the viral population shifts back and
forth between carryingmany common polymorphisms (D>0) and carryingmany unique low-
frequency variants (D<0). In contrast, the genetic structures of within-host HIV-1 populations
are more stable through time and predominated by rare or low-frequency polymorphisms (D<0;
Fig 1E). For HIV, Tajima’s D statistic gradually rises through time but rarely exceeds zero (Fig
1E). Consequently, when comparing the distributions of Tajima’s D values among the three
cohorts, for both untreated and treated HCV patients we observed significantly greater variance
and positive skew in Tajima’d D values compared to HIV-1 patients (S1 Fig). In addition, for all
groups of subjects, Tajima’s D values for each time point are positively correlated with viral
genetic diversity (S2 Fig; p<0.001 for all three groups; correlation test), such that when diversity
is low, shared mutations are more likely to be rare. Theory predicts bothMPD and Tajima’s D
values will be low when a sampled population has recently experiencedan expansion, either due
to rapid population growth or a recent selective sweep. High values of both statistics are predicted
when population structure or fluctuating selectionmaintains genetic diversity in a population.
Rates of viral molecular evolution
The mean rates of molecular evolution for each subject, as estimated using the lognormal
relaxed molecular clockmodel, are shown in Fig 2A. The mean rate is notably lower in drug-
treated HCV subjects than in the HCV untreated group (Fig 2A; Mann-Whitney U test,
p< 0.05). The evolutionary rate is in general higher for HIV-1 than for HCV (we place no
emphasis on this comparison because the HIV-1 and HCV genome regions are not homolo-
gous). Fig 2B shows, for each patient, the degree to which the viral evolutionary rate varies dur-
ing infection, which is quantified using the coefficient of variation (COV) of the relaxed
molecular clock. Two patterns are evident. First, the COV statistic is more variable among
HCV subjects than among HIV-1 subjects. Second, extremely high levels of viral rate variation
are observed in some HCV subjects, but not in HIV-1 subjects (estimated COV>1 for seven
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Fig 1. Per-sample summary statistics. (a) Mean pairwise nucleotide diversity (MPD) for each time-point
and each subject. The relative width of each circle representsMPD. Each column represents the values for
one subject (U1-7, T1-8 and H1-9). The y-axis show the time of sampling. For subjects U1-7 and H1-9, time
zero is the known (or closely estimated) date of infection. For subjects T1-8, time zero equals the date of the
first sample. (b) The distribution of MPD values is shown for each group of patients. Panels (c), (d) and (e)
show Tajima’s D estimates for each time-point and each subject. The different colours indicate different
patients. The estimates above 2 and below -2 (indicated by dashed horizontal lines) correspond to significant
deviation from neutrality. (c) Untreated HCV subjects U1-7. (d) Treated HCV subjects T1-8. (e) HIV subjects
H1-9.
doi:10.1371/journal.ppat.1005894.g001
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HCV patients, but only one HIV-1 patient). The values in some HCV subjects are unusually
high (COV>1.75) and represent exceptional rate variation among lineages (Fig 2B). To test
whether these estimates were robust to model misspecification,we implemented a new relaxed
molecular clock that assumes that branch rate scalars follow a more flexible skew-normal dis-
tribution. Unlike the standard lognormalmolecular clock, the skew-normalmolecular clock
allows the distribution of evolutionary rates among branches to be either positively or nega-
tively skewed, or non-skewed. Both the skew-normal and lognormalmolecular clocks give sim-
ilar parameter estimates (Fig 2; filled and open circles indicates estimates under log-normal
and skew-normal rate distribution, respectively). Furthermore, the shape parameter of the
skew normal model differed significantly from zero in only one patient (S3 Fig), indicating that
the distribution of among-branch rate variation was approximately symmetric.
Fig 2. Estimationof evolutionary rates. (a) Estimatedmean viral evolutionary rate for each subject in the three groups (HCV untreated,HCV treated,
and HIV). (b) Estimated coefficient of variation (COV) of the relaxed molecular clock, for each subject. Filled circles indicate estimates obtained under a
molecular clock with a log-normaldistribution of among-branch rates. Open circles indicate estimates obtained under a molecular clock with a skew-
normal rate distribution of among-branch rates. The 95% highest posterior density (HPD) intervals for each estimate are indicated by vertical error bars.
doi:10.1371/journal.ppat.1005894.g002
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To explore why rates of molecular evolution are lower in the HCV treated group than in the
untreated group (Fig 2A) we used a partitionmodel to estimate rates of evolution for first and
second codon positions (1+2cp) and third codon positions (3cp; Fig 3). These rates contain
information about the action of positive and negative selection because the majority of muta-
tions at 1+2cp and 3cp sites are, respectively, non-synonymous and synonymous. This
approach is a good proxy for dN/dS values estimated with codon substitutional models, which
for large temporally sampled datasets can be difficult to obtain due to slow MCMC conver-
gence. However, we note that, unlike dN/dS ratios, the ratio of codon position rates cannot be
used to formally test for positive selection (Table 1).
Amongst HCV subjects, 3cp rates (open squares) are largely similar between the treated
group and untreated group, whereas the 1+2cp rates (filled squares) are lower in HCV subjects
that have received treatment (Mann-Whitney U test, p<0.01; Fig 3). Thus the reduced overall
rate of virus evolution (Fig 2A) in the HCV treated group appears to be caused by reduced evo-
lution at 1+2cp sites (Fig 3), suggesting that drug-therapy has reduced the ability of the viral
population to undergo adaptive fixation (Table 1), but has not significantly reduced the fixation
of 3cp changes that are likely to be selectively neutral (see also S4 Fig). In contrast to HCV,
seven of the HIV-1 subjects had a higher estimated evolutionary rate at 1+2cp sites than at 3cp
sites (Table 1 and Fig 3), indicating greater positive selection and/or less negative selection on
the HIV-1 sequences.Many previous studies have demonstrated adaptation of the HIV-1 env
gene during infection due to positive selection (e.g. [39, 44, 45]). For HIV-1 subjects, both the
1+2cp and 3cp rates are correlated with total evolutionary rate, whereas for HCV subjects, only
the 1+2cp rate exhibits such a correlation (S4 Fig).
Phylogenetic structure and population genetic diversity
There are several notable differences between the estimated time-scaled phylogenies from
HCV subjects compared to those fromHIV-1 subjects. One representative phylogeny from
each patient group is shown in Fig 4, and all phylogenies are presented in S5–S7 Figs. The
Fig 3. Estimationof evolutionary rates for codonpartitions. Evolutionary rates for the two codon partitions(1+2 cp and 3cp) were estimated
separately for each subject. Black squares indicate the mean evolutionary rate for 1+2cp sites, and white squares indicate themean evolutionary rate
for 3cp sites. The 95%HPD intervals for each estimate are indicated by vertical error bars.
doi:10.1371/journal.ppat.1005894.g003
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vertical dashed lines indicate yearly intervals in each patient phylogeny. Firstly, during HCV
infection distinct lineages can persist for extended periods of times; in Fig 4A and 4B this can
be between 7 and 9 years, respectively. To quantify this we calculate the ratio of external to
internal branch lengths for the two HCV phylogenies in Fig 4. The mean ratios are significantly
less than one: 0.49 (95% HPD = 0.38,0.59) for the untreated HCV patient and 0.56 (0.48, 0.66)
for the treated HCV patient. In contrast the mean ratio for the HIV-1 phylogeny is 1.94 (1.65,
2.25), indicating that viral lineage turnover is faster (Fig 4C). Further, the persistent lineages
observed in HCV infectionmay go undetected for many years; hence the number of divergent
lineages that are actually detected at any given sampling timemay vary.
Secondly, HCV sequences sampled from the same time-point on the same lineage tend to
share a very recent common ancestor, giving rise to a distinctive phylogenetic pattern of
long internal branches punctuated by ‘bursts’ of closely related or identical sequences.
When only a single lineage is sampled at a given time point, this leads to a low observed
MPD and a strongly negative value of Tajima’s D. This indicates that all the HCV sequences
belonging to that lineage represent a viral subpopulation that has recently expanded or been
subjected to a recent population bottleneck. However, when multiple HCV lineages are
observed at a given time-point, then the sample MPD for that time-point is, by definition,
higher and the corresponding Tajima’s D is typically closer to zero or positive. This
Table 1. Ratio of 1+2cp and 3cp rates for each patient from the three different patient cohorts.
Patient Ratio Group
U1 0.72 HCV untreated
U2 1.77* HCV untreated
U3 0.74 HCV untreated
U4 1.43* HCV untreated
U5 0.75 HCV untreated
U6 0.31 HCV untreated
U7 0.77 HCV untreated
T1 0.45 HCV treated
T2 0.42 HCV treated
T3 0.64 HCV treated
T4 0.16 HCV treated
T5 0.36 HCV treated
T6 0.73 HCV treated
T7 0.45 HCV treated
T8 0.87 HCV treated
H1 0.77 HIV
H2 1.81* HIV
H3 1.55* HIV
H4 1.44* HIV
H5 0.82 HIV
H6 1.81* HIV
H7 1.28* HIV
H8 1.09* HIV
H9 1.16* HIV
Ratios above 1 are indicated by an asterisk (*), which is suggests higher non-synonymous rate relative to the
synonymous rate.
doi:10.1371/journal.ppat.1005894.t001
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association between phylogenetic structure and genetic diversity explains both the results
for HCV in Fig 1 and the correlation betweenMPD and Tajima’s D (S2 Fig). In comparison,
sequences sampled from a given time-point during HIV-1 infection share a comparatively
recent common ancestor on the persistent ‘backbone’ of the phylogeny (Fig 4C). Further-
more, the high ratios of external to internal branch lengths in the HIV phylogenies are
expected by theory if the viral population is unstructured and undergoing recurrent selective
sweeps. This result explains the consistently negative Tajima’s D values and the steady
changes in MPD observed for HIV-1 in Fig 1.
Changes in relative population genetic diversity during infection are illustrated by Bayes-
ian skyline plots, which are superimposed over the phylogenies in Fig 4 (the timescale of the
skyline plots and phylogenies are shared). Note that the skyline plot represents the total
diversity of the entire within-host viral population through time, including lineages that are
inferred to be present but unsampled, whereas the MPD values in Fig 1 represent only the
diversity that is actually sampled at each time point. There are no clear trends among patient
groups in the dynamics of viral population diversity, although significant declines are per-
haps more common in the HCV treated group than in either of the untreated groups (S5–S7
Figs).
Discussion
Patterns of viral genetic divergence and diversity during chronic infection depend on the struc-
ture and dynamics of the replicating viral population, and therefore they provide a source of
information about infection kinetics that is independent from and complementary to mathe-
matical models of longitudinal viral load measurements [8–11]. Further, molecular clock
approaches like those used here may better resolve complex evolutionary dynamics than analy-
ses of sequence summary statistics, which uses data less efficiently [46]. The results of our evo-
lutionary analyses show that intra-patient HCV evolution is exceptionally heterogeneous, both
within and among different subjects, compared with intra-patient HIV-1 evolution, and that
Fig 4. Phylogenetic structure.Amaximumclade credibility phylogeny is shown for one representative subject from each patient group (HCV untreated,
HCV treated, and HIV). Branches are scaled by time. Superimposed on each phylogeny, on the same timescale, is the estimatedBayesian skyline plot for
that subject. The light grey line indicates themean skyline plot estimate of effective population size through time. The darker grey areas indicate the 95%
highest posterior density credible interval for that estimate. The distance between dotted vertical lines indicates one year. (a) Patient U3 from the HCV
untreated group. (b) Patient T1 from the treatedHCV group. (c) Patient H2 from the HIV cohort.
doi:10.1371/journal.ppat.1005894.g004
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this variation is present in both treated and untreated HCV-infected subjects. Specifically, for
HCV we find (i) extreme heterogeneity in the rate of molecular evolution in some patients; (ii)
a lower rate of non-synonymous change in patients that received interferon-treatment; (iii) sig-
nificant fluctuations in viral genetic diversity through time; and (iv) unusual phylogenetic
topologies containing multiple distinct lineages that coexist for long periods of time, combined
with ‘bursts’ of closely-related sampled variants. These observations are not consistent with a
well-mixed viral population with homogenous infection dynamics, but instead suggest that
HCV infections are comprised of multiple sub-populations with distinct evolutionary and rep-
lication behaviours.
While rates of HCVmolecular evolution in vivo are comparable to those estimated for other
RNA viruses (e.g. HIV-1 and influenza) [47], we observe very high among-lineage rate hetero-
geneity only for some HCV infections. This suggests, at the very least, that circulatingHCV
lineages do not all accumulate substitutions in the same manner. Rates of viral sequence diver-
gence are determined by mutation rates, population sizes, generation times, and mutational
selection coefficients.Crucially, the latter three factors can only vary within an individual if the
within-patient viral population is split into distinct subpopulations with separate dynamics.
There is a growing body of independent evidence that indicates the presence of an HCV
population structure in the liver. The existence of genetically distinct viral sub-populations
(compartmentalization) has been demonstrated for viruses isolated from (i) plasma versus
liver [29, 30, 48–53], (ii) different locations within the same liver [32], and (iii) between non-
tumourous liver tissue versus tumour-associated liver tissue [32, 54–57]. Experimental studies
demonstrate that, within the liver, HCV tends to be localized to specific foci of infection [18]. If
cell-to-cell transmission is more efficient than transmission via free virions, then models of
HCV infection should incorporate local viral replication, adaptation and spread within the
organ [58]. Viral population structuremay also exist outside the liver, as HCV genetic com-
partmentalisation has been reported (i) among cirrhotic liver samples [50], (ii) between plasma
and PBMCs [29, 30, 49, 53, 59–61], (iii) between PBMCs and the liver [29–31, 49, 59], (iv)
between liver and perihepatic lymph nodes [53], and (iv) in the brain [62].
The heterogeneity in HCV evolutionary rate we report here is consistent with these experi-
mental results, and we posit that it arises from distinct sub-populations of HCV (hepatic or
extra-hepatic) whose replication is modulated by local fluctuations in host cell availability and
turnover, and/or by anti-viral immune responses. The modulation of replication within sepa-
rate viral sub-populations can also readily explain the unusual HCV phylogenetic topologies.
Specifically, HCV lineages that are present in the body, but which are not directly observed in
peripheral blood for prolonged periods of time, might represent sub-populations that are not
shedding virions into circulation, either because they are replicating slowly, or because they are
transmitting via cell-to-cell contact. Cell-to-cell transmission may allow HCV to replicate in
the presence of neutralizing antibodies [14, 58] and is again consistent with the detection of
hepatic foci of infection [18, 20]. One recent study has found that in vitro DAA drug-resistant
viruses predominantly spread by this route of transmission [16]. Further, the ‘bursts’ of closely
related sequences that we observe are consistent with the recent and rapid growth of previously
restricted viral subpopulations. The causes of these bursts are unknown; possible explanations
include viral adaptation or the local deterioration of immune control.
Viral population structure and host immune responses could also account for the puzzling
fact that most cells in the liver are uninfected [18, 35, 63]. This is surprising given that viral
loads in serum are high (105–107 virions/mL), and that transplant livers are rapidly re-infected
following transplantation. If the viral population is strongly structured then chronic infection
requires only the establishment of a few long-lasting sub-populations that are not removed by
host immune responses. It is not known whether the distinct lineages observedduring HCV
Exceptional Heterogeneity in Viral EvolutionaryDynamics Characterises Hepatitis C Virus Infection
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infection are antigenically distinct. If they are, this antigenic variation may contribute to the
creation and maintenance of a persistent infection.
The highly structured nature of HCV intra-host genetic diversity also has consequences for
the evolutionary analysis of chronic infection. Specifically, it means that samples of HCV diver-
sity from peripheral blood do not adequately characterise the genetic diversity of the infection
as a whole [46]. We find that statistics of sample diversity (MPD and Tajima’s D) vary substan-
tially through time within HCV subjects, but are more consistent (Tajima’s D) or less skewed
(MPD) for HIV-1 subjects.Molecular clock phylogenetic analyses show that this is due to sig-
nificant among lineage rate variation.Whilst PCR primers might fail to amplify some within-
host HCV lineages, it is difficult to conceive how differential amplification might cause strong
fluctuations in viral diversity through timewithin a single patient.
Given that the number of sequences per time point in our data sets is comparatively small
(range n = 18 to n = 88) it could be argued that the intermittent detection of HCV lineages in
peripheral blood is solely a consequence of sampling uncertainty. To explore this, let us sup-
pose there are two lineages, in which case the probability of detection can be determined by the
binomial distribution. If n = 40 and sampling is random, then a lineage whose population fre-
quency is 5% will be detected at 87% of timepoints, but a lineage whose frequency is 0.5% will
be seen at only 4% of timepoints. Lineages at frequencies between ~0.5% and ~5% are therefore
likely to be intermittently detected in our study. However the key observation that HCV line-
ages are often dominant at one timepoint, but rare or absent at a later timepoint, is not an arte-
fact of sampling uncertainty because the sample sizes used in our study will almost certainly
detect all lineages whose frequencies exceed 15%.We also note that the evolutionary patterns
in HCV subjects reported here have come from different cohorts generated using different
sequencing approaches, and similarly structuredwithin-host HCV phylogenies have been
noted elsewhere [64–66]. Although we cannot pinpoint the anatomical locations of HCV
genetic sub-populations, these are likely to be sites within the liver and/or extra-hepatic com-
partments such as PBMCs or the central nervous systems [30, 62]. Cross-sectional genetic anal-
ysis of HCV diversity in explanted livers may help to address this question.
Low recombination in HCV [67] could also potentially explain differences between the
within-host molecular evolution of HIV-1 and HCV. Specifically, infrequent recombination
can lead to stronger clonal interference, whereby beneficialmutations on different genetic
background compete for fixation [68], resulting in longer times to fixation of mutations and
increased diversity at each sampling time.While this effect is likely to shape HCVmolecular
evolution, and may increase the length of some internal phylogenetic branches, it cannot
account for the alternating appearance of divergent lineages in peripheral blood after long peri-
ods of absence. Further, low recombination would lead to complete selective sweeps and is
therefore inconsistent with the long-term persistence of multiple lineages (e.g.> 20 years in
one treated HCV subject; see S6C Fig) observed in our HCV cohorts.
The hypothesis that strong HCV population structure and lineage rate variation contributes to
viral persistence has consequences for the newDAAs that are highly successful in treating HCV
infection.Although these treatments drastically reduce treatment times, a longer-follow up of
patients may be prudent if there is a longer-term risk of viral relapse from unsampled reservoir
populations within the body. A recent study has found that viral persistence is prevalent in patients
who have spontaneously resolved the virus [69]; HCV RNA was detected in ~70% of patients ~6
years after clearing the virus. Furthermore, samples collected from PBMCs between 5 to 20 years
after initial detectionof HCV supports ongoing viral replication despite patients appearing non-vir-
aemic [69]. Very late HCV breakthroughs have been reported from some clinical trials using DAA
therapy [23–25]. Although these instances are infrequent, they do highlight that our understanding
of the persistence of HCV at low levels is inadequate and requires further investigation.
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Lastly, the high evolutionary heterogeneity of HCV within hosts has important implications
for molecular epidemiological analyses of HCV genetic diversity at the among-host level. In
such studies each infected individual is typically represented by a single sequence that is inter-
preted as the ‘consensus’ of the within-host viral population at the time of sampling. For HCV,
the intermittent detection in sera of diverse lineages means that the consensus sequence
obtainedmay be highly dependent on when sampling occurs, and may not be representative of
the virus that is transmitted. Crucially, this could explain in part why among-host HCVmolec-
ular clock phylogenies have proven difficult to calibrate from longitudinal samples of HCV
sequences [70].
Materials andMethods
Datasets
We analysed a total of 15 HCV infected subjects. Subject and sampling information is provided
in Tables S1-3. Subjects from previously published studies were only included if HCV
sequences were sampled longitudinally for at least 5 years. HCV sequences were obtained from
seven untreated patients previously reported by [43, 71] (referred to as U1-U7 in this study).
These subjects acquired HCV infection either perinatally (U1-3) [43] or via transfusion (U4-7)
[71]. The date of infectionwas known and thus all time points represent time since infection.
To enable direct comparison with other subjects, HCV sequences sampled during acute infec-
tion were removed (U1, U4, U6: time points<3 months; U5: time points<9 months; U7: time
points<8 months). The sequences represent partial E1/E2 gene sequences corresponding to
positions 1308–1835 relative to the H77 HCV reference genome. Alignments from these
patients included a total of 2246 sequences (range 235–418 sequences per subject) and an aver-
age of 8.7 time points per subject (range 6–12 time points) that cover an average duration of
sampling of 13.6 years (range 7.4–23.3 years).
Sequences from an additional 8 subjects were obtained from sequential serum samples from
a cohort of HCV patients from Bari, Italy. The hypothesised route of transmission was nosoco-
mial infection following surgery: no other risk factors were observed and all patients were anti-
HCV negative at the time of surgery, however none of them received a blood transfusion.
These subjects (denoted T1-8) were treated with interferon and ribavirin; all subjects received
at least one period of therapy during the study, although duration and regimen varied among
subjects. Sequences from these subjects were generated by amplifying segments of the E1/E2
gene region using multiple different primer pairs that spanned the hyper-variable region 1
(HVR1). Full sequencing details for this cohort can be found in Supporting Information (S1
Text). Sequences were trimmed to match those obtained from patients U1-7 and corresponded
to positions 1320–1799 relative to the H77 HCV reference genome. At least 18 clonal
sequences were generated per time-point. Alignments from subjects T1-8 included a total of
1980 sequences (range 132–395 per subject), with an average of 7.3 time points per subject
(range 4–10) covering an average of 7.9 years of infection (range 5.2–8.8 years). The HVR1
region was targeted for sequencing in both untreated and treated HCV cohort as it is the most
diverse region in the HCV genome, and consequently contains the strongest phylogenetic sig-
nal compared to other, more conserved genomic regions. A comparable set of previously pub-
lished sequences from a cohort of untreated HIV-1 infected subjects (HIV1-9) was analyzed
concurrently [72]. All subjects were infected with subtype B and sequences represented the
C2-V5 region of the gp120 gene (corresponding to positions 7023–7286 in the HXB2 HIV ref-
erence genome). The total number of HIV-1 sequences was 1028 (range 52–160 per subject),
with an average of 11.7 time points per subject (range 6–15) spanning an average of 8.2 years
of infection (range 6.1–11.2).
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To verify and subtype the HCV sequences, an alignment was created containing the HCV
sequences from all 15 subjects, plus reference sequences from each of the major HCV subtypes
and genotypes. A neighbour-joining tree was reconstructed under the HKY nucleotide substi-
tution model using MEGAv5.0 [73]. Two hundred bootstrap replicates were used to assess the
robustness of the tree topology. Sequences from each subject clustered with each other, and not
with sequences from other subjects, with high bootstrap support. In the untreated cohort, sub-
jects were singly infected with subtypes 1a, 1b, and 4d, while in the treated cohort all patients
were infected with subtype 1b.
Per-sample summarystatistics
The genetic diversity of the intra-host viral population at each time point in each subject was
estimated by calculatingmean pairwise genetic distances among sequences using a Tamura-
Nei substitution model with gamma distributed rates, as implemented in MEGA5.0 [73].
We also calculated Tajima’s D statistic for each sampling time in each subject, using DNAsp
[74]. Tajima’s D statistic describes the relative frequency of common versus rare polymor-
phisms in the sample, and consequently describeswhether the sample phylogeny is star-like
(long external branches) or structured (long internal branches). Tajima’s D is expected to be
zero under a null model of constant size population with no natural selection or population
structure. Negative D values indicate an excess of rare polymorphisms compared to this null
model, which may result from a recent selective sweep or population growth. Positive D values
indicate an excess of common polymorphisms, which may be caused by population contrac-
tion, or population structure, or by fluctuating selection.
Estimation of evolutionary rates
Rates of within-host molecular evolution (divergence rates) were investigated using the Bayes-
ian Markov chain Monte Carlo framework implemented in BEAST v.1.8 [75]. An initial set of
model selection analyses were undertaken to explore different coalescent and molecular clock
models (in each case the codon-structured SDR06 nucleotide substitution model was used).
Simple coalescentmodels (constant size and exponential growth) failed to converge for some
HCV datasets, so final analyses were performed using the Bayesian Skyline coalescentmodel.
Preliminary analyses indicated significant among-branch rate heterogeneity so a relaxed
uncorrelated molecular clock was used. Analyses were first performed using the standard log-
normal distributionmodel, for which the among-branch rate distribution is negatively skewed.
However, we were concerned that this model may not adequately capture the rate variation in
within-host HCV evolution. Therefore we also implemented a newmolecular clock model in
BEAST 1.8 with a skew-normal distribution of among-branch rate variation, which allows the
among branch rate distribution to be either positively or negatively skewed, or unskewed (see
S2 Text for example XML code). Evolutionary rates were also estimated separately for (i) com-
bined 1st and 2nd codon positions (1+2cp) and (ii) 3rd codon positions (3cp), using a log-nor-
mal molecular clock model. MCMC convergence was generally slow and chain length varied
between 100–200 million generations. Chains were sampled regularly to yield 10000 samples.
Multiple independent runs were undertaken to ensure adequate mixing and stationarity had
been achieved, as diagnosed using trace plots and effective sample sizes.
Exploring the potential effects of sequence undersampling
Our historical data sets were generated using clonal Sanger sequencing and contain far fewer
sequences per time point (n = 18–88) than could be generated using modern next-generation
sequencing (NGS) platforms (100s or 1000s of sequences per time point). To explore the
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potential effects of this on our estimates of statistics of viral genetic diversity, we simulated the
process of undersampling upon previously published NGS datasets for both chronic HIV and
HCV infections.We looked for NGS within-host data sets within which we could identify non-
overlapping regions of varying genetic diversity that were 350-400nt length and which were
represented at depth of 500 reads or greater. Suitable HIV data was found in Zanini et al [76]
and Dialdestoro et al [77], and comparable HCV data was obtained from Lu et al [78].
We randomly subsampled these NGS datasets to simulate the effects of undersampling. Spe-
cifically, in each case, we generated 100 randomly subsampled datasets containing 5, 10, 12, 14,
16, 18, 20, 40, 60, 80, and 100 sequences. For each replicate subsample we estimated mean
MPD and Tajima’s D in exactly the same way as for the real data (see above). These results are
summarized in S8 and S9 Figs.
In all cases, the variability and uncertainty in estimates of MPD and Tajima’s D drops
quickly as sample size (n) increases above 10. In our data sets, sample sizes per timepoint range
from n = 18 to n = 88 (shown in S8 and S9 Figs as red dashed lines). In this range of sample
sizes, estimates of MPD and Tajima’s D are close to those obtained from the full (non-subsam-
pled) dataset. In general, variance in estimates of these statistics stabilises between n = 5 and
n = 18 sequences, and this is seen in both low and high diversity genome regions. This indicates
that our estimates of MPD and Tajima’s D (Fig 1) are very similar to those that would be
obtained fromNGS data sets comprising hundreds or thousands of reads, and that the
observedvariation in these statistics among time points is not due to sampling uncertainty (or
small sample sizes); instead the variation is due to real changes in the viral population.While
NGS datasets would undoubtedly reveal many more rare variants, such variants have very little
effect, by definition, on statistics that summarise the genetic composition of the population as a
whole.
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Supporting Information
S1 Fig. Distribution of Tajima’s D values for three cohorts.The distributions of Tajima’s D
values are plotted for each cohort (HCV untreated, HCV treated, and HIV-1). The HCV
untreated and treated groups have very similar distribution of Tajima’s D values, which show
greater positive skew and variance compared to HIV-1 patients.
(PDF)
S2 Fig. Correlation betweenTajima’s D andmean pairwisenucleotide diversity (MPD).
Tajima’s D (x-axis) is plotted against pair-wise nucleotide diversity (y-axis) for all time-points
and subjects. (a) HCV untreated group; (b) HCV treated group; (c) HIV-1 group. A fitted lin-
ear regression model and associated R2 value are shown for each group.
(PDF)
S3 Fig. Mean estimate of the shape parameter of the skew-normal relaxedmolecular clock
model.Mean estimate (filled circle) and 95% confidence intervals (vertical bars) of the shape
parameter (y-axis) are shown for all subjects (x-axis).
(PDF)
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S4 Fig. Correlation among evolutionary rates estimated from different alignment parti-
tions.Mean estimate of the evolutionary rate for first and second codon positions (y-axis, both
panels) is plotted against (a) the total mean evolutionary rate for all sites, and (b) the mean evo-
lutionary rate for third codon positions. Each point represents a different subject. Subjects in
the untreated HCV group are shown as open circles, those in the treated HCV group as filled
circles, and those in the HIV-1 group as red squares. A fitted linear regression model and asso-
ciated R2 value are shown for HCV and HIV-1 groups.
(PDF)
S5 Fig. Demographic history of untreated HCV subjects.The maximum clade credibility
tree and skyline plots are shown each subject group. Panels (a) to (g) represent subjects U1-7,
respectively. Seemain text Fig 4 for more details. Trees and skyline plots were inferred using
the log-normal relaxed molecular clock model. Dotted vertical lines indicate one year and
branches are scaled by time. The light grey line indicates the mean population diversity esti-
mates through time, and the darker grey areas indicate the 95% HPD intervals of that estimate.
(PDF)
S6 Fig. Demographic history of treated HCV subjects.The maximum clade credibility tree
and skyline plots are shown each subject group. Panels (a) to (h) represent subjects T1-8,
respectively. Seemain text Fig 4 for more details. Trees and skyline plots were inferred using
the log-normal relaxed molecular clock model. Dotted vertical lines indicate one year and
branches are scaled by time. The light grey line indicates the mean population diversity esti-
mates through time, and the darker grey areas indicate the 95% HPD intervals of that estimate.
(PDF)
S7 Fig. Demographic history of HIV-1 subjects.The maximum clade credibility tree and sky-
line plots are shown each subject group. Panels (a) to (i) represent subjects HIV1-9, respec-
tively. Seemain text Fig 4 for more details. Trees and skyline plots were inferred using the log-
normal relaxed molecular clockmodel. Dotted vertical lines indicate one year and branches are
scaled by time. The light grey line indicates the mean population diversity estimates through
time, and the darker grey areas indicate the 95% HPD intervals of that estimate.
(PDF)
S8 Fig. The effect of undersampling on estimates of pairwisediversity and Tajima’s D from
within host HCV sequence data. Three deep-sequenceddatasets from Lu et al (2013), which
represent three HCV subtype 1a infections (HCV isolates 1106, 1701, and 1706, respectively)
were analysed to explore the potential effects of undersampling on estimating population
genetic summary statistics. Specifically, we chose three genome regions of varying levels of
diversity (the columns are ordered by increasing diversity, from left to right), whereMPD indi-
cates the mean pairwise diversity based on the full dataset. In each case, we generated 100 ran-
domly subsampled datasets containing 5, 10, 12, 14, 16, 18, 20, 40, 60, 80, and 100 sequences.
For each replicate, we estimatedMPD and Tajima’s D in exactly the same way as for the real
data. The red dashed lines correspond to the sample sizes used in the current study (n = 18 to
n = 88). Panels A-C summarize the results for HCV isolates 1106, 1701, and 1709, respectively.
(PDF)
S9 Fig. The effect of undersampling on estimates of pairwisediversity and Tajima’s D from
within host HIV-1 sequence data.Appropriate HIV-1 datasets from Zanini et al (2016) and
Dialdestoro et al (2016) were analysed to test the effects of sampling on estimating pairwise
diversity and tajima’s D in HIV-1 within-host viral population. As in S8 Fig, three non-over-
lapping genomic regions were chosen, 350-400nt long. These genomic regions were selected to
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represent regions of low to high diversity, and each was required to have a minimum depth of
500 sequences. In each case, we generated 100 randomly subsampled datasets containing 5, 10,
12, 14, 16, 18, 20, 40, 60, 80, and 100 sequences. For each replicate, we estimatedMPD and
Tajima’s D in exactly the same way as for the real data. The red dashed lines correspond to the
sample sizes used in the current study (n = 18 to n = 88). Panels A and B represent patients 1
and 3 (at timepoints 11 and 5, respectively), from Zanini et al (2016), while panel C represents
patient 3 sampled at day 108 from Dialdestoro et al (2016).
(PDF)
S1 Table. HCV Subjects.
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(DOCX)
S3 Table. Primer combinations for amplification of HCV envelope.
(DOCX)
S1 Text. Sequencing information for treated HCV subjects.
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